PL2696889T3 - Warianty ludzkiego GDNF - Google Patents

Warianty ludzkiego GDNF

Info

Publication number
PL2696889T3
PL2696889T3 PL12712874T PL12712874T PL2696889T3 PL 2696889 T3 PL2696889 T3 PL 2696889T3 PL 12712874 T PL12712874 T PL 12712874T PL 12712874 T PL12712874 T PL 12712874T PL 2696889 T3 PL2696889 T3 PL 2696889T3
Authority
PL
Poland
Prior art keywords
variants
human gdnf
gdnf
human
Prior art date
Application number
PL12712874T
Other languages
English (en)
Polish (pl)
Inventor
Donmienne Doen Mun Leung
Jirong Lu
Kalpana Mahesh Merchant
Mahmoud Ghanem
Linda Maureen O'bryan
Rosamund Carol Smith
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL2696889T3 publication Critical patent/PL2696889T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL12712874T 2011-04-11 2012-04-03 Warianty ludzkiego GDNF PL2696889T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474024P 2011-04-11 2011-04-11
PCT/US2012/031927 WO2012141936A1 (en) 2011-04-11 2012-04-03 Variants of human gdnf
EP12712874.2A EP2696889B1 (en) 2011-04-11 2012-04-03 Variants of human gdnf

Publications (1)

Publication Number Publication Date
PL2696889T3 true PL2696889T3 (pl) 2018-04-30

Family

ID=45932578

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12712874T PL2696889T3 (pl) 2011-04-11 2012-04-03 Warianty ludzkiego GDNF

Country Status (28)

Country Link
US (1) US9243046B2 (cg-RX-API-DMAC7.html)
EP (1) EP2696889B1 (cg-RX-API-DMAC7.html)
JP (1) JP6093345B2 (cg-RX-API-DMAC7.html)
KR (1) KR101554799B1 (cg-RX-API-DMAC7.html)
CN (1) CN103635201B (cg-RX-API-DMAC7.html)
AU (1) AU2012243178B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013026004B1 (cg-RX-API-DMAC7.html)
CA (1) CA2833158C (cg-RX-API-DMAC7.html)
CY (1) CY1119750T1 (cg-RX-API-DMAC7.html)
DK (1) DK2696889T3 (cg-RX-API-DMAC7.html)
EA (1) EA025129B1 (cg-RX-API-DMAC7.html)
ES (1) ES2656020T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171993T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036239T2 (cg-RX-API-DMAC7.html)
IL (1) IL228102A (cg-RX-API-DMAC7.html)
LT (1) LT2696889T (cg-RX-API-DMAC7.html)
ME (1) ME02849B (cg-RX-API-DMAC7.html)
MX (1) MX337206B (cg-RX-API-DMAC7.html)
NO (1) NO2696889T3 (cg-RX-API-DMAC7.html)
PL (1) PL2696889T3 (cg-RX-API-DMAC7.html)
PT (1) PT2696889T (cg-RX-API-DMAC7.html)
RS (1) RS56639B1 (cg-RX-API-DMAC7.html)
SG (1) SG193483A1 (cg-RX-API-DMAC7.html)
SI (1) SI2696889T1 (cg-RX-API-DMAC7.html)
TW (1) TWI583698B (cg-RX-API-DMAC7.html)
UA (1) UA112981C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012141936A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306556B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190142868A1 (en) 2016-05-13 2019-05-16 Instituto de Medicina Moleccular Methods of treating diseases associated with ilc3 cells
US20230022970A1 (en) * 2019-12-19 2023-01-26 Transfert Plus, Société En Commandite Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
JP2024522938A (ja) 2021-06-03 2024-06-21 フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2119463C (en) 1991-09-20 2003-09-16 Leu-Fen H. Lin Glial cell line-derived neutrophic factor
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
DE19816186A1 (de) 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
CN101775072B (zh) 2008-05-21 2012-09-05 王尚武 一种融合穿透肽的神经细胞营养因子gdnf
ES2545614T3 (es) * 2009-02-06 2015-09-14 Pepscan Systems Bv Proteínas truncadas con nudo de cistina

Also Published As

Publication number Publication date
IL228102A (en) 2017-04-30
CA2833158A1 (en) 2012-10-18
UA112981C2 (uk) 2016-11-25
RS56639B1 (sr) 2018-03-30
NO2696889T3 (cg-RX-API-DMAC7.html) 2018-04-14
IL228102A0 (en) 2013-09-30
TW201245220A (en) 2012-11-16
HUE036239T2 (hu) 2018-06-28
EP2696889A1 (en) 2014-02-19
MX337206B (es) 2016-02-17
ZA201306556B (en) 2015-03-25
US9243046B2 (en) 2016-01-26
CY1119750T1 (el) 2018-06-27
KR101554799B1 (ko) 2015-09-21
JP2014512369A (ja) 2014-05-22
CN103635201A (zh) 2014-03-12
CA2833158C (en) 2018-07-17
AU2012243178A1 (en) 2013-09-05
AU2012243178B2 (en) 2016-09-29
ES2656020T3 (es) 2018-02-22
CN103635201B (zh) 2016-11-09
HRP20171993T1 (hr) 2018-02-09
JP6093345B2 (ja) 2017-03-08
TWI583698B (zh) 2017-05-21
LT2696889T (lt) 2018-02-12
NZ614325A (en) 2015-07-31
BR112013026004A2 (pt) 2016-11-29
SI2696889T1 (en) 2018-01-31
EA201370204A1 (ru) 2014-02-28
PT2696889T (pt) 2018-02-05
ME02849B (me) 2018-01-20
KR20130131470A (ko) 2013-12-03
BR112013026004B1 (pt) 2020-09-29
MX2013011919A (es) 2014-03-27
SG193483A1 (en) 2013-10-30
DK2696889T3 (en) 2018-01-22
EP2696889B1 (en) 2017-11-15
US20130324474A1 (en) 2013-12-05
EA025129B1 (ru) 2016-11-30
WO2012141936A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
ZA201308417B (en) Tissue healing
EP2717855A4 (en) PROCESSING METHODS
ZA201304280B (en) Treatment of jak2-mediated conditions
ZA201301601B (en) Treatment of diseases
IL233111A0 (en) Preparations for the treatment of inflammation
EP2671565A4 (en) EXTERNAL PREPARATION FOR THE SKIN
PL3287131T3 (pl) Terapeutyczne zastosowania ektoiny
IL225896A0 (en) Treatment of mecp-2 related disorders
GB201501016D0 (en) Preparation of 18F-fluciclovine
ZA201308194B (en) Treatment of mastitis
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
ZA201306556B (en) Variants of human gdnf
ZA201308176B (en) Therapeutic treatment
GB201107467D0 (en) Novel treatment of pain
GB201102913D0 (en) Novel therapeutic
GB201104632D0 (en) Use of medicament
GB201100651D0 (en) Treatment of inflammation
ZA201404348B (en) Treatment of seborrhoea
GB201109737D0 (en) Methods of treatment
GB201110602D0 (en) Methods of treatment
AU2011902407A0 (en) Treatment of pain
GB201121044D0 (en) Treatment of solutions
GB201204645D0 (en) Treatment of disease
GB201107536D0 (en) Preparation of organopolysiloxanes
GB201118065D0 (en) Treatment of movement disorders